NEWBURY PARK, Calif.–(BUSINESS WIRE)–Compulink Healthcare Solutions, the creator of Advantage SMART Practice®, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), will showcase its Dermatology Advantage™ suite of dermatology-specific solutions at the American Society for Dermatologic Surgery’s annual meeting from October 24-26, 2019 in Chicago, IL.
Designed to maximize efficiencies and improve profitability, Advantage uses real-time data to automate tasks and streamline patient flow. Features include:
“Our goal is to maximize the efficiency of the entire staff during the patient encounter to drive down costs and improve the patient experience,” said Link Wilson, CEO and product architect for Compulink. “Our Advantage SMART Practice solution handles all of the needs of a patient encounter, reducing repetitive steps to enable the practice to see more patient with the same staff and improve their bottom line by as much as 40%.”
Designed to maximize efficiencies and improve profitability, Advantage includes dermatology-specific EHR, practice management, inventory management, and mobile patient engagement. The company also provides an expert revenue cycle management service for its clients. Advantage is 2015 ONC Certified for MIPS and is used by more than 20,000 providers in over 4,700 locations, 60 ASCs, and 19 universities and colleges.
Attendees at ASDS can demo Dermatology Advantage™at booth 506.
About Compulink Healthcare Solutions
A leader in specialty-specific, all-in-one EHR and Practice Management solutions for 34 years, Compulink’s Advantage SMART Practice® uses artificial intelligence to improve clinical and financial results. Designed to maximize your time while seeing patients, Advantage includes everything you need to optimize workflow including EHR, PM, ASC, patient engagement, and RCM.
Contacts
Compulink Healthcare Solutions
Mary Ann Fitzhugh
p. 800.456.4522
e. press@compulinkadvantage.com
WASHINGTON & BERLIN--(BUSINESS WIRE)--Association of Medical Device Reprocessors issued the following statement: Friday’s unanimous verdict…
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patientswith Mild and Moderate-to-Severe Symptoms,…
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and…
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time…
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in…
TORONTO, May 17, 2025 (GLOBE NEWSWIRE) -- Today, on DIPG Awareness Day, Brain Cancer Canada…